Skip to main content
Premium Trial:

Request an Annual Quote

HP Exec Says Partnerships, Itanium Tech Will Ensure Success in Life Science Market

Premium

When Hewlett-Packard spun off Agilent Technologies in 1999, it appeared that its interest in the life sciences went with it. But David Valenta, HP’s global marketing development manager for life sciences, told BioInform that the company is a solid contender in the life sciences computing market.

Despite a relatively late entry into the sector and stiff competition from Sun, IBM, and Compaq, Valenta is confident that the company’s strategy of partnering with software and solution providers will give it an edge in the market. “We focus on designing and building the best computers, the best network, the best infrastructure, the best storage, and so on, and we let the life sciences software and solutions experts design the products in the various vertical markets,” he said.

Valenta said that HP has identified life sciences as a “significant growth area” over the next year.

Some industry observers have suggested that HP’s proposed merger with Compaq would give the combined company a competitive advantage over IBM and Sun in this market. Compaq has already secured a number of key clients in the sector, and some see the merger as proof of HP’s renewed focus on the life sciences.

Valenta declined to comment on the proposed merger and what impact it may have on HP’s life science activities.

He noted that although HP didn’t enter the life sciences market until two years ago, the company has already secured a number of important partners and customers in the sector and is increasing its presence significantly.

 

First Fruits in Pharma

 

HP’s ebntry strategy for the life sciences market began by building relationships with software and service providers with whom it already had strong relationships in manufacturing and IT infrastructure to serve large pharmaceutical companies. “We provide solutions all the way from research through clinical trials,” said Valenta, noting that most hardware providers have limited their focus to the research and discovery end of the pipeline. “Most of the people buying solutions for clinical trials buy our mid-range and high-end servers,” Valenta added.

In addition, HP has forged a number of academic partnerships ó including the University of Washington in Seattle and Washington University in St. Louis ó through which it helps ensure that university code runs on HP equipment. Valenta said the company is currently finalizing a deal with “a large university in the US” for a 242-cpu Superdome Unix/Linux system for life sciences and computational chemistry.

While admitting that HP had yet to fully penetrate the biotech sector, Valenta said, “You can bet we’re acting on our opportunities.” Current partners within this sphere include Viaken Systems, Lion Bioscience, and Geospiza.

HP’s plan is to “offer biotechs something they can’t get from someone else,” Valenta said. That may come in the form of financing, an option HP used in its partnership with Viaken, or in technical strengths not available from competitors.

Viaken, which uses HP’s OpenView platform for its managed services and hosting, may be a crucial partner as HP seeks to gain more market share within the sector. “The top-tier market that [hardware] companies have sought is limited in the pharmaceutical and biotech market,” said Keith Elliston, CEO of Viaken. “HP was progressive in partnering with us to gain access to the mid-tier market, which has the biggest share and opportunity.”

Furthermore, Elliston predicted that the likely HP/Compaq merger would “strengthen our position and their position in reaching the small- to mid-sized biotech.” He noted that Compaq’s focus on high-performance computing for the life sciences should complement HP’s reputation for “highly reliable, maintainable systems.”

 

The Itanium Issue

 

Valenta said that the Itanium chip, which HP developed with Intel, offers a number of benefits for life science customers, particularly smaller companies. He noted that HP-UX is the only commercial Unix currently available on Itanium. The advantage is that “customers can buy one piece of hardware and then decide what they want to run on it ó Linux, NT, HP-UX, it doesn’t matter.” Valenta added that HP-UX applications are binary compatible with Itanium, “so you don’t have to recompile if you don’t want to, which is another advantage for our life science customers.”

“We’re excited about Itanium,” said Elliston. “We like to find platforms that can support multiple operating systems and our data structures and our compute needs really benefit from a 64-bit architecture.”

Elliston added that “Itanium really takes on a new kind of importance” in light of Compaq’s recent decision to phase out its Alpha technology in favor of the Itanium architecture. The impending HP/Compaq merger should reassure Compaq’s Alpha customers that the transition to Itanium will be a smooth one, Elliston said.

Valenta said that HP also offers enabling tools, such as its Praesidium suite of security software, which is of great interest to the life science sector. “Pharma is very concerned about security,” Valenta said, noting that a pharmaceutical company recently opted for HP’s solutions “strictly because of our robust and complete security products.”

Although the life sciences is currently a very small portion of HP’s business, as it is for all hardware providers, Valenta cited IDC’s recent forecast for 52 percent growth over the next three years as evidence that the life science market will be an important focus for the company’s technical computing business. “Even if that’s an over-optimistic figure and it’s only 30 percent growth, that’s still good,” he added.

But HP is certainly not the only hardware provider to recognize the enormous revenue potential within the life sciences. IBM’s vice president of life sciences, Caroline Kovac, told Reuters last week that the life sciences market is a “triple-digit growth area” for her company, and that IBM expects the market to generate sales of $1 billion or more within three years.

A merger with Compaq should only improve HP’s chances for beating IBM in this market. “Before the [merger announcement], if you said, ëWhat is IBM’s competition in this space?’ it didn’t look strong,” said Elliston. “But with HP-Compaq you combine HP’s very strong professional service base with Compaq’s life science focus, and you’ve got an immediate competitor to IBM.”

— BT

Filed under

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.